# Construction of a prognostic model based on palmitoylation-related lncRNAs for assessing drug benefits in breast cancer

**Authors:** Yan Wang, Mengsi Zhang, Yuqin Zhou, Zaozhuo Li, Xinglin Yi, Lin Ren, Yi Zhang

PMC · DOI: 10.3389/fimmu.2025.1656593 · Frontiers in Immunology · 2025-10-27

## TL;DR

This study builds a model using specific long non-coding RNAs to predict breast cancer prognosis and drug response, identifying two key lncRNAs linked to tumor growth and protein modification.

## Contribution

A novel prognostic model based on palmitoylation-related lncRNAs for breast cancer, identifying two key lncRNAs and their potential regulatory roles.

## Key findings

- AC016394.2 and AC022150.4 are significantly associated with tumor cell growth, proliferation, and migration.
- The two lncRNAs may regulate SEC24C and ZNF611 through co-expression and enhance their palmitoylation.
- The model shows predictive power for prognosis and drug sensitivity in breast cancer.

## Abstract

The lncRNAs associated with protein palmitoylation in breast cancer (BC) remain largely unexplored.

We retrieved transcriptome, proteome, and mutation data from TCGA-BRCA (BC), identified 592 palmitoylation-related lncRNAs (PRLs), constructed a prognostic model (PmPRLs) based on their characteristics. According to the score of the median risk, the “High-”and “Low” risk groups were distinguished. The predictive potential of PmPRLs for the prognosis of BC was determined through Kaplan-Meier (KM) survival analysis, ROC curve analysis, and risk scoring verification using the training set and validation set. The differences of PmPRLs in different risk groups were illustrated by using gene mutation frequency, immune function, tumour immune dysfunction and rejection (TIDE) score and drug sensitivity analysis. Based on this model, key feature LncRNAs were screened out. After the identified LncRNAs were verified by the external dataset TANRIC, a series of tumour phenotypic experiments were conducted to comprehensively demonstrate their role in tumourigenesis and development.

We identified 2 key feature lncRNAs, AC016394.2 and AC022150.4, as the most significant prognostic factors. Both of these lncRNAs exhibited high expression levels in the TCGA and TANRIC datasets and were closely associated with tumour cell growth, proliferation, and migration. More importantly, based on co-expression analysis, we proposed that AC016394.2 and AC022150.4 may respectively regulate SEC24C and ZNF611. Furthermore, these two lncRNAs enhanced the palmitoylation modification of these proteins.

The insights regarding the potential roles of AC016394.2 and AC022150.4 can enhance our understanding of the mechanisms towards the pathogenesis and progression of BC.

## Linked entities

- **Genes:** SEC24C (SEC24 homolog C, COPII component) [NCBI Gene 9632], ZNF611 (zinc finger protein 611) [NCBI Gene 81856]
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** SEC24C (SEC24 homolog C, COPII component) [NCBI Gene 9632], ZNF611 (zinc finger protein 611) [NCBI Gene 81856], BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}
- **Diseases:** breast cancer (MESH:D001943), tumour (MESH:D009369)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12597904/full.md

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12597904/full.md

## References

16 references — full list in the complete paper: https://tomesphere.com/paper/PMC12597904/full.md

---
Source: https://tomesphere.com/paper/PMC12597904